6:25 PM
 | 
Jul 13, 2015
 |  BC Extra  |  Clinical News

Allegro reports Phase II Luminate data in vitreoretinal disease

Allegro Ophthalmics LLC (San Juan Capistrano, Calif.) said the highest of three Luminate ( ALG-1001) doses met the primary endpoint in a Phase II trial to treat vitreomacular...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >